

Prevalence of PER and VEB Type Extended Spectrum Betalactamases among Multidrug Resistant *Acinetobacter baumannii* Isolates in North-West of Iran

Safar Farajnia^{1,2*}, Fatemeh Azhari², Mohammad Yousef Alikhani³, Mohammad Kazem Hosseini⁴, Amir Peymani⁵, Nasrolah Sohrabi⁶

¹ Drug Applied Research Center, Tabriz University of Medical Science, Tabriz, Iran

² Biotechnology Research Center, Tabriz University of Medical Science, Tabriz, Iran

³ Microbiology Department, Hamadan University of Medical Science, Hamadan, Iran

⁴ Istanbul University, Faculty of Sciences, Molecular Biology and Genetic, Istanbul, Turkey

⁵ Microbiology Department, Qazvin University of Medical Science, Qazvin, Iran

⁶ Paramedical Faculty, Kermanshah University of Medical Sciences, Kermanshah, Iran

ARTICLE INFO

Article type:
Original article

Article history:
Received: Jun 11, 2012
Accepted: Oct 23, 2012

Keywords:
Acinetobacter baumannii
Extended spectrum
betalactamases
Integron class I

ABSTRACT

Objective(s): Drug resistant *Acinetobacter baumannii* have emerged as a major problem in many hospitals and intensive care units. Various types of extended spectrum beta-lactamases (ESBLs) are responsible for resistance to beta-lactam antibiotics in different parts of the world. The objective of this study was to determine the prevalence of integron class1 (INT 1) and ESBL types PER-1, PER-2 and VEB-1 among *A. baumannii* strains isolated from Tabriz, North-West of Iran.

Material and Methods: A total of 100 *A. baumannii* isolates collected from different clinical samples were included in the study. Antimicrobial susceptibility profiles were determined using the Kirby Bauer disk diffusion method. Production of ESBL was investigated by testing resistance against ceftazidime, cefotaxime, ceftriaxone and verified by Double Disk Synergy Test. DNA was extracted from the isolates and the frequency of INT 1 and ESBL types PER-1, PER-2 and VEB-1 were determined by PCR using specific primers.

Results: Among 100 *A. baumannii* isolates screened, 80 isolates were multidrug-resistant and 70 isolates were positive for ESBL production. PCR screening revealed that 74 % of the isolates contained class 1 integron, 51% were positive for PER-1 gene, 10% positive for VEB1 whereas none of the isolates were positive for PER2 type gene.

Conclusion: This is the first report of ESBL types VEB and PER in *A. baumannii* from North West of Iran. The results of this study demonstrated high prevalence of PER-1 and VEB-1 type ESBLs among *A. baumannii* isolates in the study region and reminded the necessity of appropriate infection control strategy to prevent further spread of infection by these organisms.

► Please cite this paper as:

Farajnia S, Azhari F, Alikhani MY, Hosseini MK, Peymani A, Sohrabi N. Prevalence of PER and VEB Type Extended Spectrum Betalactamases among Multidrug Resistant *Acinetobacter baumannii* Isolates in North-West of Iran. Iran J Basic Med Sci; 2013; 16: 751-755.

Introduction

Acinetobacter is a Gram-negative, aerobic, non-fermentative coccobacilli that has gained special attentions as a nosocomial opportunistic pathogen. Nutritional requirements of this bacterium are simple and they easily grow on most environmental conditions. *Acinetobacter* can survive on different medical equipments and even on healthy human skin (1). The multidrug-resistant *A. baumannii* (MDRAB) are defined as *A. baumannii* isolates that are resistant to at least three different classes of antimicrobial agents mainly betalactams, aminoglycosides, fluoroquinolones and carbapenems (2). There are increasing reports of MDRAB

outbreaks in various clinical settings worldwide (3, 4). Carbapenems are currently the drugs of choice in the treatment of severe infections caused by this organism; however, carbapenem resistant *A. baumannii* is now reported increasingly throughout the world (5-8).

Extended spectrum beta lactamases (ESBLs) are a class of group A beta lactamases which results in hydrolysis of first, second, and third generation cephalosporines but are inhibited by beta-lactamase inhibitors like Acid clavulanic (9-11). Classic extended spectrum beta lactamases are originated from the plasmid encoding ESBLs of TEM (Temoneira) /SHV (sulphydryl variable), and OXA

*Corresponding author: Safar Farajnia, Drug Applied Research Research Center, Daneshgah Ave., Tabriz, Iran. Tel: +98-4113363234, Fax: +98-4223363231; email: farajnias@tbzmed.ac.ir

Table 1. The sequence of primers accompanied with their annealing temperatures and expected PCR product sizes

Primer	Primer sequences	Annealing temperature	Product size (bp)
VEB-F	5'-GAAACAACCTTTGACGATTGA-3'	50°C	370
VEB-R	5'-CCCTGTTTATGAGCAACAA-3'		
PER1-F	5'-ATGAATGTCATTATAAAAGC-3'	50°C	925
PER1-R	5'-AATTTGGGCTTAGGGCAGAA-3'		
PER2-F	5'-GTAGTATCAGCCCAATCCCC-3'	50°C	738
PER2-R	5'-CCAATAAAGGCGTCCATCA-3'		
INT-1-F	5'-GGTGTGGCGGGCTTCGTG-3'	55°C	456
INT-1-R	5'-GCATCCTCGGTTTTCTGG-3'		
OXA-51F	5'-ACAAGCGCTATTTTATTTCAG-3'	51°C	641
OXA-51R	5'-CCCATCCCAACCACTTTT-3'		

(oxacillinase) families. But in recent years, new families of extended spectrum beta lactamases have Vietnamese extended-spectrum beta-lactamase families (13). Plasmid is responsible for the distribution of most beta lactamases, however, the gene encoding for these enzymes may also be on the chromosomes or transposable elements, integrons (14). Five different classes of integrons have been found among which INT-1 is the most common type found in the gram negative bacilli and clinical isolates of *A. baumannii* (2, 15). It has shown that carriage on integrones facilitates the spread of resistance genes among bacteria.

This study was carried out to determine the prevalence of integron class I, PER and VEB type ESBLs among *A. baumannii* strains isolated from patients hospitalized in Imam Reza Hospital of Tabriz, in Northwest of Iran.

Materials and Methods

Bacterial isolation and identification

In this study, a total of 100 non-duplicate isolates of *A. baumannii* were collected from a University Hospital in Tabriz city located in Northwest of Iran between March 2008 and June 2009. The isolates were from different clinical samples including tracheal secretion, bronchial lavage, blood, wound, sputum, abscess drainage, peritoneal fluid, and urine. Identification of the isolates were performed using standard microbiological tests such as; Gram stain, oxidase test, growth at 44°C and O/F test.

Antimicrobial susceptibility of isolates

Antimicrobial susceptibility of isolates was determined by Kirby Bauer disk diffusion method using Clinical Laboratory Standard Institute (CLSI) guidelines. A single pure colony was inoculated into 3 ml of normal saline and vortexed to mix well. The inoculum size was standardized by comparison of the turbidity of the bacterial suspension with 0.5 McFarland Standard. A sterile cotton-tipped swab was dipped into the suspension and used to lawn the bacterial suspension onto the Muller Hinton agar plate. The antibiotic discs cefotaxime (30 µg), cefixime (5 µg), ceftizoxime (30 µg), ceftazidime (30 µg), ceftriaxone (30 µg), cephalixin (30 µg), cephalotin (30 µg),

also emerged all over the world (12), including PER (for *Pseudomonas* extended resistance) and VEB (for tetracycline (30 µg), ciprofloxacin (5 µg), cotrimoxazole (25 µg), kanamycin (30 µg), ticarcilin (75 mg), polymixin B (300 µg), tobramycin (10 µg), chloramphenicol (30 µg), norfloxacin (10 µg), ofloxacin (5 µg), amikacin (30 µg), gentamicin (10 µg), ampicillin (10 µg), carbenicillin (100 µg), rifampin (5 µg), colistin (110 µg) (MAST, Merseyside, UK) were then placed on the plates and incubated at 37°C overnight. The diameter of inhibition zones was measured using the CLSI guidelines. *Escherichia coli* ATCC 25922 and *Pseudomonas aeruginosa* ATCC 27853 were used as controls.

Detection of ESBL production by double disc synergy test

After inoculation of the isolates on Muller Hinton agar media an amoxicillin-clavulanic acid disc was placed in the center of plate and the cefotaxim, ceftazidim, cefpime and azteronam discs were placed in a distance of 10 mm from the central disc and 20 mm from each other. Plates were incubated at 37°C for 18 hr and the increase in the sensitivity zone and its intend toward amoxicillin-clavulanic acid disc was considered as positive for production of ESBL.

DNA Extraction and PCR amplification

All *A. baumannii* isolates were grown for 18 hr at 37°C in MacConkey agar and DNA was extracted by SDS-Proteinase K phenol chloroform method as described (16). Briefly, 4-5 fresh colonies was resuspended in 300 µl of TE buffer, SDS (1%) and proteinase K (10 µg/ml), and incubated at 40°C for 3 hrs followed by phenol-chloroform extraction and ethanol precipitation. Finally, DNA was dissolved in distilled water and quality and concentration of the DNA was checked with a spectrometer and on a 1% agarose gel.

Detection of PER1, PER-2, VEB-1 and class I integron in clinical isolates of *A. baumannii* was carried out by PCR with primers illustrated in the Table 1. OXA51 PCR was also performed for confirmation of the identity of isolates. PCR master mix components were as follows; 10X PCR buffer in final concentration of 1X, MgCl₂ (50mM) in a final concentration of 1.5 mM, dNTP

Table 2. Sources of *Acinetobacter baumannii* isolates

Source	Frequency (%)
Tracheal	37%
Urine	21%
Sputum	9%
Blood	7%
Catheter	6%
Bronchial washing	6%
wound	5%
Abscess drainage	3%
CSF	2%
Pleural effusion	2%
Ascites fluid	2%
Total	100%

mix, 10 mM in a final concentration of 0.2 mM and forward and reverse primers in a final concentration of 0.4 μ M. PCR amplification was performed in a total volume of 25 μ l (24 μ l of PCR master mix plus 1 μ l of template DNA).

PCR amplification conditions were as follows: initial denaturation at 94°C for 4 min followed by 35 cycles of 60 sec denaturation at 94°C, 60 sec annealing at primers annealing temperature (Table 1) and 45 sec extension at 72°C with a final extension at 72°C for 7 min. PCR products were analyzed by electrophoresis in 1.2% agarose gel in a TAE buffer at 90 volts alongside with DNA ladder. The gel was then stained with ethidium bromide for 20 min and finally visualized in gel documentation system.

Results

Patients and Bacterial isolation

A total of 100 *A. baumannii* isolates were obtained from patients that had been admitted to the university hospital of Imam Reza in Tabriz, North-West of Iran. The isolates were obtained from different clinical samples including the respiratory system specimens (54%), urine (21%), blood (7%), catheter (6%), and other sources (12%) (Table 2). 37% of the isolates were from hospitalized patients in the intensive care units (ICU). The age range of the patients was from 14 to 86 years old. The isolates were obtained from patients belonging to different age groups: 20-39 years (n = 25), 40-59 (n = 39), 60-90 years (n = 33) and three isolates were from patients less than 20 years old. 29 % of patients sustained trauma and invasive procedures such as intubation and tracheostomy were used for 63% of patients.

Bacterial identification

Biochemical tests revealed that all isolates belonged to *A. baumannii* species. Analysis for presence of *bla*_{OXA-51-like} gene demonstrated that all isolates were positive for *bla*_{OXA-51-like} gene that confirmed their identity as *A. baumannii*.

Antibiotic susceptibility testing

The drug resistance pattern of isolates has been shown in Table 3. The highest resistance rate was

against cefixime and ceftizoxim whereas the lowest resistances were to polymyxin B (16%), colicitin (19%) and ampicillin-sulbactam (55%). 62% and 63% of isolates were resistant to imipenem and meropenem, respectively. Double disc synergy test analysis revealed that 70% of isolates were ESBL positive.

ESBL Genotypes

Screening for PER-1, PER-2 and VEB-1 genotypes by PCR among ESBL positive isolates revealed that 51% of isolates were positive for PER1 gene (Figure 1) whereas VEB-1 determinant were positive in 10 % of isolates (Figure 2). None of the isolates were positive for PER-2 ESBL gene. PCR amplification for INT-1 gene showed that 73% of isolates contained the INT-1 insertion sequence (Figure 3).




Figure 1. PCR amplification of PER-1 resistance gene among ESBL positive *Acinetobacter baumannii* isolates.




Figure 2. PCR amplification of VEB-1 resistance gene among ESBL positive *Acinetobacter baumannii* isolates.




Figure 3. PCR amplification of Int-1 mobile element among *Acinetobacter baumannii* isolates.

Table 3. Antimicrobial resistance pattern of *Acinetobacter baumannii* against different antibiotics

Antimicrobial agent	Resistance (%)	Antimicrobial agent	Resistance (%)
Cefpodoxime	100	Co-Trimixazole	79
Ceftizoxime	100	Gentamicin	78
Cefixime	100	Ciprofloxacin	78
Ticarcilin	100	Levofloxacin	76
Aztreonam	97	Meropenem	63
Ceftriaxone	94	Imipenem	62
Ceftazidime	92	Ampicillin-sulbactam	55
Ampicillin	91	Colistin	19
Cefepime	88	Polymixin B	16

Discussion

Nosocomial infections are a major source of mortality and morbidity in hospitalized patients (17) and *A. baumannii* plays an important role in these infections due to its resistance against multiple classes of antibiotics (18). Production of ESBLs is one of the main mechanisms for antibiotic resistance in gram negative bacteria including *A. baumannii* and detection of ESBL production and related genotypes is critical for surveillance of drug resistance in different geographic regions.

In this study, the rate of ESBL production, the prevalence of ESBL genotypes PER1, PER-2, VEB-1 and the presence of INT-1 gene were investigated in *A. baumannii* isolates recovered from patients hospitalized in Emam-Reza Hospital of Tabriz which is the largest university hospital in North-west region of Iran.

Findings of the present study showed that 70% of the studied *Acinetobacter* isolates were positive for ESBL. This indicates a high frequency of resistance due to ESBL in the studied cases. Previous reports from Iran showed the ESBL production in 39 % of *A. baumannii* (19) which indicates an increase in the rate of antibiotic resistance due to ESBL.

Screening for PER-1 genotype revealed that 51% of *A. baumannii* isolates contained PER-1 gene. This results is similar to the reports which were published by researchers from Turkey (46%) (19) and South Korea (54.6%) (20) and indicates that PER-1 is the most common ESBL genotype in *A. baumannii*.

Investigation through PCR for VEB-1 type ESBL showed that among 70 ESBL positive isolates, VEB-1 gene was positive in 10% of cases that all belonged to MDRAB isolates. Literature review for VEB-1 shows that the prevalence of this ESBL varies in different part of the world. VEB-1 type ESBL in *A. baumannii* was reported for the first time by Laurent Poirel in 58.33% of isolates in France in 2003 (21). In a study performed by Thierry Naas and his colleagues in Belgium in 2006, 6 out of 8 isolates of *A. baumannii* were positive for VEB-1 (22) whereas Pasteran and Rapopot was reported VEB-1 in 47.61% of isolates in the USA (23). Also, VEB type ESBL reported in 4 out of 6 clinical *A. baumannii* isolates (66 %) in Argentina (24). It has been shown that integrons are one of the main factors in carriage

and distribution of drug resistant genes among bacteria. In this study, the screening for INT-1 gene by PCR showed that among 70 ESBL positive isolates the INT-1 gene were positive in 63.3% of cases. In a study carried out by Francesca Gomac and his colleagues in Italy, 16 out of 36 *A. baumannii* isolates (44%) contained integron I (25) whereas Javier Ariza and his colleagues found integron I in 27.53% of *A. baumannii* isolates in Spain (15). A recent report from China (2) showed integron class I in 71.4% (202 out of 283) of *A. baumannii* isolates, which is consistent with our findings in this research.

In this study, none of the isolates were positive for PER-2 gene. Few studies have been carried out about PER-2 gene in the world. This type of ESBL was identified for the first time in *A. baumannii* isolates in the U.S.A in 2006 (23). Also, Poirel and his colleagues (2007) reported PER-2 gene in one out of 6 (16.6%) *A. baumannii* isolates in Argentina. It seems that either PER-2 type ESBL distribution is restricted to some specific geographic regions or it may not have been studied in other parts of the world.

The results of this study also revealed that 37% of *A. baumannii* isolates were from patients hospitalized in the ICU wards most of whom (79%) were ESBL positive. It may not be surprising since it has already been shown that ICU stay and long term antibiotic use in these patients is one of the risk factors that predispose patients for *A. baumannii* infections (26).

Conclusion

This study revealed high antimicrobial resistance among *A. baumannii* isolates in the study region. The ESBL type PER and VEB played an important role in this antimicrobial resistance reminding the necessity of appropriate preventive policy in hospitals to control further spreading of these highly resistant strains.

References

1. Murray PR, Baron EJ, Pfaller MA, Tenover FC, Tenover FC. Manual of Clinical Microbiology. 7th ed. Washington, D.C: ASM Press; 1999. p. 517- 525.
2. Huang LY, Chen TL, Lu PL, Tsai CA, Cho WL, Chang FY, et al. Dissemination of multidrug-resistant, class 1 integron-carrying *Acinetobacter baumannii* isolates in Taiwan. Clin Microbiol Infect 2008; 14:1010-1019.

3. Nowak-Zaleska A, Krawczyk B, Kotłowski R, Mikucka A, Gospodarek E. Amplification of a single-locus variable-number direct repeats with restriction fragment length polymorphism (DR-PCR/RFLP) for genetic typing of *Acinetobacter baumannii* strains. *Pol J Microbiol* 2008; 57:11-17.
4. Peleg AY, Seifert H, Paterson DL. Successful Pathogen *Acinetobacter baumannii*: Emergence of a10.1128/CMR.00058-07. *Clin Microbiol Rev* 2008; 21:538.
5. Marais E, G de Jong, Ferraz V, Maloba B, Duse AG. Interhospital transfer of pan-resistant *Acinetobacter* strains in Johannesburg, South Africa. *Am J Infect Control* 2004; 32:278-281.
6. Merkier AK, Catalano M, Ramírez MS, Quiroga C, Orman B, Ratier L, et al. Polyclonal spread of *bla*OXA-23 and *bla*OXA-58 in *Acinetobacter baumannii* isolates from Argentina. *J Infect Dev Ctries* 2008; 2:235-240.
7. Coelho J, Woodford N, Afzal-Shah M, Livermore D. Occurrence of OXA-58-Like Carbapenemases in *Acinetobacter* spp. collected over 10 years in three continents. *Antimicrob Agents Chemother* 2006; 50:756-758.
8. Dijkshoorn L, Nemec A, Seifert H. An increasing threat in hospitals: multidrug-resistant *Acinetobacter baumannii*. *Nat Rev Microbiol* 2007; 5:939-951.
9. Bradford PA. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. *Clin Microbiol Rev* 2001; 14:933-951.
10. Jacoby GA, Munoz-Price LS. Mechanisms of disease the new β -Lactamases. *N Engl J Med* 2005; 352:380-3891.
11. Gniadkowski M. Evolution and epidemiology of extended-spectrum β -lactamases (ESBLs) and ESBL-producing microorganisms. *Clin Microbiol Infect* 2001; 7:597-608.
12. Bush k. New beta-lactamases in gram negative bacteria: diversity and impact on the selection of antimicrobial therapy. *Clin Infect Dis* 2001; 32:1085-1089.
13. Stürenburg E, Mack D. Extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory, therapy, and infection control. *J Infect* 2003; 47:273-295.
14. Rasheed JK, Jay C, Metchock B, Berkowitz F, Weigel L, Crellin J, et al. Evolution of extended-spectrum β -lactam resistance (SHV-8) in a strain of *Escherichia coli* during multiple episodes of bacteremia. *Antimicrob Agents Chemother* 1997; 41:647-653.
15. Ribera A, Vila J, Fernández-Cuenca F, Martínez-Martínez L, Pascual A, Beceiro A, et al. Spanish Group for Nosocomial Infection (GEIH). Type 1 integrons in epidemiologically unrelated *Acinetobacter baumannii* isolates collected at Spanish hospitals, American Society for Microbiology. *Antimicrob Agents Chemother* 2004; 48:364-365.
16. Yousefi S, Farajnia S, Nahaei MR, Akhi MT, Ghotaslou R, Soroush MH, et al. Detection of metallo- β -lactamase-encoding genes among clinical isolates of *Pseudomonas aeruginosa* in northwest of Iran. *Diagn Microbiol Infect Dis* 2010; 68:322-5.
17. García-Garmendia JL, Carlos OL, José GM, Francisco-Javier J-J, Carmen P-P, Ana EBA, et al. Risk Factors for *Acinetobacter baumannii* Nosocomial Bacteremia in Critically Ill Patients :A Cohort Study. *Clin Infect Dis* 2001; 33: 939-946.
18. Perez F, Hujer AM, Hujer KM, Decker BK, Rather PhN, Bonomo RA. Global challenge of multidrug-resistant *Acinetobacter baumannii*. *Antimicrob Agents Chemother* 2007; 51:3471-3484.
19. Vahaboglu H, Oztürk R, Aygün G, Coşkunkan F, Yaman A, Kaygusuz A, et al. Wide- spread detection of PER-1-type extended-spectrum beta-lactamases among nosocomial *Acinetobacter* and *Pseudomonas aeruginosa* isolates in Turkey: A nationwide multicenter study. *Antimicrob Agents Chemother* 1997; 41:2265-2269.
20. Yong D, Shin JH, Kim S, Lim Y, Yum JH, Lee K, et al. High prevalence of PER-1 extended-spectrum beta-lactamase-producing *Acinetobacter* spp. in Korea. *Antimicrob Agents Chemother* 2003; 47:1749-1751.
21. Poirel L, Menuteau O, Agoli N, Cattoen C, Nordmann P. Outbreak of extended-spectrum beta-lactamase VEB-1-producing isolates of *Acinetobacter baumannii* in a French Hospital. *J Clin Microbiol* 2003; 41:3542-3547.
22. Naas T, Bogaerts P, Bauraing C, Degheldre Y, Glupczynski Y, Nordmann P. Emergence of PER and VEB extended-spectrum beta-lactamases in *Acinetobacter baumannii* in Belgium. *J Antimicrob Chemother* 2006; 58:178-82.
23. Pasterán F, Rapoport M, Petroni A, Faccone D, Corso A, Galas M, et al. Emergence of PER-2 and VEB-1a in *Acinetobacter baumannii* Strains in the Americas. *Antimicrob Agents Chemother* 2006; 50:3222-3224.
24. Poirel L, Corvec S, Rapoport M, Mugnier P, Petroni A, Pasteran F, et al. Identification of the novel narrow-spectrum β -lactamase SCO-1 in *Acinetobacter* spp. from Argentina. *Antimicrob Agents Chemother* 2007; 51:2179-2184.
25. Gombac F, Riccio ML, Rossolini GM, Lagatolla C, Tonin E, Monti-Bragadin C, et al. Molecular characterization of integrons in epidemiologically unrelated clinical isolates of *Acinetobacter baumannii* from Italian hospitals reveals a limited diversity of gene cassette arrays. *Antimicrob Agents Chemother* 2002; 46:3665-3668.
26. Fournier PE, Richet H. The epidemiology and control of *Acinetobacter baumannii* in health care facilities. *Clin Infect Dis* 2006; 42:692-699.